DK2833907T3 - Sammensætninger og fremgangsmåder til at inhibere masp-1 og/eller masp-3 til behandlingen af paroxystisk nokturn hæmoglobinuri - Google Patents
Sammensætninger og fremgangsmåder til at inhibere masp-1 og/eller masp-3 til behandlingen af paroxystisk nokturn hæmoglobinuri Download PDFInfo
- Publication number
- DK2833907T3 DK2833907T3 DK13798222.9T DK13798222T DK2833907T3 DK 2833907 T3 DK2833907 T3 DK 2833907T3 DK 13798222 T DK13798222 T DK 13798222T DK 2833907 T3 DK2833907 T3 DK 2833907T3
- Authority
- DK
- Denmark
- Prior art keywords
- masp
- lea
- inhibitory agent
- seq
- complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (10)
1. Sammensætning omfattende en mængde af et MASP-3-inhiberende middel effektivt til at inhibere MASP-3-afhængig komplement-aktivering til anvendelse i behandling af et individ, der lider af paroxystisk nokturn hæmoglobinuri (PNH), hvor nævnte MASP-3-inhiberende middel er et monoklonalt MASP-3-antistof eller fragment deraf, der specifikt binder til en del af human MASP-3 (SEQ ID NO:8).
2. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen yderligere omfatter mindst et af: et MASP-l-inhiberende middel, et MASP-2-inhiberende middel, en kombination af et MASP-l-inhiberende middel og et MASP-2-inhiberende middel, og/eller en terminal komplement-inhibitor, der inhiberer spaltning af komplement-protein C5.
3. Sammensætning til anvendelse ifølge krav 2, hvor det MASP-l-inhiberende middel er mindst et af: (i) et monoklonalt MASP-l-antistof, eller fragment deraf, der specifikt binder til en del af SEQ ID NO: 10; (ii) et MASP-l-inhiberende middel, der specifikt binder til en del af MASP-1 med en affinitet på mindst 10 gange større end det binder til MASP-3 (SEQ ID NO:8); og/eller (iii) et MASP-l-inhiberende middel, der specifikt binder til serin-protease-domænet af MASP-1 (aa 449-694 af SEQ ID NO: 10).
4. Sammensætning til anvendelse ifølge krav 2, hvor det MASP-2-inhiberende middel er et monoklonalt MASP-2-antistof, eller fragment deraf, der specifikt binder til en del af SEQ ID NO:5.
5. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor sammensætningen øger overlevelsen af røde blodlegemer i et individ, der udviser et eller flere symptomer valgt fra gruppen bestående af (i) under normale hæmoglobinniveauer, (ii) under normale blodpladeniveauer; (iii) over normale retikulocytniveauer, og (iv) over normale bilirubinniveauer; eventuelt hvor individet tidligere har gennemgået, eller er i gang med at gennemgå behandling med en terminal komplement-inhibitor, der inhiberer spaltning af komplementprotein C5.
6. Sammensætning til anvendelse ifølge krav 2, hvor den terminale komplementinhibitor er et humaniseret anti-C5-antistof eller antigen-bindende fragment deraf, eller hvor nævnte inhibitor er eculizumab.
7. Sammensætningen ifølge krav 1 hvor det monoklonale MASP-3-antistof eller fragmentet deraf er valgt fra gruppen bestående af et rekombinant antistof, et antistof med reduceret effektorfunktion, en kimær, og et humaniseret eller humant antistof.
8. Sammensætningen ifølge krav 1, hvor sammensætningen er formuleret til systemisk indgivelse, såsom til subkutan, intramuskulær, intravenøs, intraarteriel indgivelse eller indgivelse som inhalationsmiddel.
9. Sammensætning til anvendelse ifølge krav 1, omfattende en mængde af et MASP-3-inhiberende middel effektivt til at øge overlevelsen af røde blodlegemer i et individ, der lider af paroxystisk nokturn hæmoglobinuri (PNH).
10. Sammensætning til anvendelse ifølge krav 9, yderligere omfattende et MASP-2-inhiberende middel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261621461P | 2012-04-06 | 2012-04-06 | |
PCT/US2013/035488 WO2013180834A2 (en) | 2012-04-06 | 2013-04-05 | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2833907T3 true DK2833907T3 (da) | 2018-05-28 |
Family
ID=49325295
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18158799.9T DK3366307T3 (da) | 2012-04-06 | 2013-04-05 | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri |
DK13798222.9T DK2833907T3 (da) | 2012-04-06 | 2013-04-05 | Sammensætninger og fremgangsmåder til at inhibere masp-1 og/eller masp-3 til behandlingen af paroxystisk nokturn hæmoglobinuri |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18158799.9T DK3366307T3 (da) | 2012-04-06 | 2013-04-05 | Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri |
Country Status (29)
Country | Link |
---|---|
US (3) | US20130273053A1 (da) |
EP (2) | EP3366307B1 (da) |
JP (3) | JP6366571B2 (da) |
KR (2) | KR102142508B1 (da) |
CN (1) | CN104661676A (da) |
AU (3) | AU2013267909B2 (da) |
BR (1) | BR112014024793A2 (da) |
CA (2) | CA2869326C (da) |
CL (1) | CL2014002694A1 (da) |
CY (1) | CY1120736T1 (da) |
DK (2) | DK3366307T3 (da) |
ES (2) | ES2894944T3 (da) |
HK (1) | HK1206996A1 (da) |
HR (1) | HRP20180671T1 (da) |
HU (1) | HUE036930T2 (da) |
IL (2) | IL234991B (da) |
IN (1) | IN2014KN02324A (da) |
LT (1) | LT2833907T (da) |
MX (2) | MX2018008658A (da) |
NO (1) | NO2881536T3 (da) |
NZ (2) | NZ629675A (da) |
PL (2) | PL3366307T3 (da) |
PT (1) | PT2833907T (da) |
RS (1) | RS57266B1 (da) |
RU (2) | RU2018114903A (da) |
SI (1) | SI2833907T1 (da) |
TR (1) | TR201806939T4 (da) |
WO (1) | WO2013180834A2 (da) |
ZA (1) | ZA201408100B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2704743B1 (en) * | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
RS61755B1 (sr) * | 2012-06-18 | 2021-05-31 | Omeros Corp | Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja |
US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
US20150017162A1 (en) | 2013-03-15 | 2015-01-15 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
EP3546574A4 (en) * | 2016-11-28 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN AND POLYPEPTIDE BINDING AREA INCLUDING A TRANSPORT SECTION |
WO2018186322A1 (en) * | 2017-04-03 | 2018-10-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-masp-1 antibodies and methods of use |
SG11202010925UA (en) * | 2018-05-29 | 2020-12-30 | Omeros Corp | Masp-2 inhibitors and methods of use |
CA3148119A1 (en) * | 2019-07-31 | 2021-02-04 | Biocryst Pharmaceuticals, Inc. | Dosing regimens for oral complement factor d inhibitors |
IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
CN114295594B (zh) * | 2021-12-06 | 2023-09-19 | 贵州理工学院 | 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
ATE149841T1 (de) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | Impfstoffe gegen krebs und infektionskrankheiten |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
AU785149B2 (en) * | 1999-12-02 | 2006-10-05 | Jens Christian Jensenius | MASP-3, a complement-fixing enzyme, and uses for it |
SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
US7043719B2 (en) * | 2001-07-23 | 2006-05-09 | Intel Corporation | Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations |
CA2490007C (en) | 2002-07-19 | 2011-05-24 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
JP2006518749A (ja) * | 2003-02-21 | 2006-08-17 | タノックス インコーポレーテッド | 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法 |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US20070253949A1 (en) * | 2004-02-03 | 2007-11-01 | Stefan Golz | Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1) |
US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
DE602006004582D1 (de) * | 2006-07-31 | 2009-02-12 | Fiat Ricerche | Durch eine Fluidströmung betätigbarer elektrischer Generator |
EP2152861B1 (en) | 2007-05-31 | 2017-03-22 | University of Washington | Inducible mutagenesis of target genes |
WO2010034441A1 (en) * | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
WO2010080833A1 (en) * | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
KR20110134415A (ko) * | 2009-03-05 | 2011-12-14 | 스미스 앤드 네퓨, 인크. | 대퇴경부 안내 와이어를 배치하기 위한 시스템, 방법 및 장치 |
AU2010272483B2 (en) * | 2009-07-17 | 2016-07-21 | Omeros Corporation | MASP isoforms as inhibitors of complement activation |
KR20120130748A (ko) * | 2009-11-05 | 2012-12-03 | 알렉시온 캠브리지 코포레이션 | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 |
KR20220044616A (ko) * | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Masp-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
-
2013
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/en active Active
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 CA CA2869326A patent/CA2869326C/en active Active
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/en active Active
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/en active Application Filing
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 CA CA3087933A patent/CA3087933A1/en active Pending
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/da active
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
-
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
-
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
-
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
-
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
-
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220089781A1 (en) | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | |
DK2833907T3 (da) | Sammensætninger og fremgangsmåder til at inhibere masp-1 og/eller masp-3 til behandlingen af paroxystisk nokturn hæmoglobinuri | |
EP2861246B1 (en) | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders | |
AU2017276333B2 (en) | Methods for treating conditions associated with MASP-2 dependent complement activation | |
AU2013201627B2 (en) | Methods for treating conditions associated with MASP-2 dependent complement activation |